Ligands with its PDB code and its tanimoto calculated from the molecule, present in the database, which has for MMscode: MMs02447682
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
You can sort the columns by Ligand, Ligand name, PDB and Tanimoto.
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
---|---|---|---|---|---|
Ligand | Ligand name | Chain | PDB | Tanimoto | Ligand in PDB |
318 | N'-[(1S,2S)-2-[(4S)-1-benzyl-5- oxoimidazolidin-4-yl]-1-(3,5-difluorobenzyl)- 2-hydroxyethyl]-5-methyl-N,N-dipropylbenzene- 1,3-dicarboxamide | A,B | 3CID | 0.74 | |
0E2 | N-acetyl-L-valyl-O-benzyl-L-threonyl- N-[(1R,2R)-2-hydroxy-1-{[(3R)-2- oxopyrrolidin-3-yl]methyl}propyl]- L-leucinamide | A | 2Z3C | 0.74 | |
485 | [2-AMINO-3-(4-HYDROXY-PHENYL)-PROPIONYLAMINO]- (3,4,5-TRIHYDROXY-6-METHYL-TETRAHYDRO- PYRAN-2-YL)- ACETIC ACID | A | 1JIL | 0.72 | |
0PN | N-[(benzyloxy)carbonyl]-L-valyl- L-alanyl-N~5~-[amino(iminio)methyl]- L-ornithyl-L-serine | A | 3G8F | 0.84 | |
5FH | (5S)-5-benzylimidazolidine-2,4- dione | A | 2JLO | 0.7 | |
0E4 | N-acetyl-L-tyrosyl-L-valyl-L-alanyl- L-aspartic acid | B,D | 3GJS | 0.74 | |
0E3 | N-acetyl-L-valyl-O-benzyl-L-threonyl- N-[(1R)-2-oxo-1-{[(3S)-2-oxopyrrolidin- 3-yl]methyl}propyl]-L-leucinamide | A | 2Z3C | 0.73 | |
316 | N'-[(1S,2S)-2-[(2S)-4-benzyl-3- oxopiperazin-2-yl]-1-(3,5-difluorobenzyl)- 2-hydroxyethyl]-5-methyl-N,N-dipropylbenzene- 1,3-dicarboxamide | A,B | 3CIC | 0.73 | |
4PH | 4-methyl-L-phenylalanine | B,C | 3BV9 | 0.71 | |
0Z6 | D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}- 1-(chloroacetyl)butyl]-L-phenylalaninamide | H,L | 3ELA | 0.75 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A,B | 2P3C | 0.72 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A | 2P3D | 0.72 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A,B | 2P3B | 0.72 | |
3TL | BENZYL (2S,5S,8S,9R,10R,11S,14S,17S)- 8,11-DIBENZYL-9,10-DIHYDROXY-5,14- DIISOPROPYL-3,6,13,16-TETRAOXO- 4,7,12,15-TETRAAZAOCTADECANE-2,17- DIYLDICARBAMATE | A,B | 2P3A | 0.72 | |
0EZ | tert-butyl [(1S,2S)-1-benzyl-2- hydroxy-3-{[(8S,11R)-8-[(1R)-1- methylpropyl]-7,10-dioxo-2-oxa- 6,9-diazabicyclo[11.2.2]heptadeca- 1(15),13,16-trien-11-yl]amino}propyl]carbamate | A,B | 1MTR | 0.71 | |
1BH | N-BENZYLOXYCARBONYL-ALA-PRO-3-AMINO- 4-PHENYL-BUTAN-2-OL | A | 1BH6 | 0.76 | |
15M | (5Z)-7-{(1R,2R,3R,5S)-3,5-DIHYDROXY- 2-[(1E,3S)-3-HYDROXY-5-PHENYLPENT- 1-ENYL]CYCLOPENTYL}-N-ETHYLHEPT- 5-ENAMIDE | A | 2F38 | 0.72 | |
002 | N-[(2R)-2-BENZYL-4-(HYDROXYAMINO)- 4-OXOBUTANOYL]-L-ISOLEUCYL-L-LEUCINE | A,B | 2FV9 | 0.78 | |
0G6 | D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}- 1-(chloroacetyl)butyl]-L-prolinamide | B,H,L | 3DD2 | 0.74 | |
0G6 | D-phenylalanyl-N-[(1S)-4-{[amino(iminio)methyl]amino}- 1-(chloroacetyl)butyl]-L-prolinamide | B,D,F,H | 1XMN | 0.74 | |
45U | (S)-N-(4-carbamimidoylbenzyl)-1- (2-(cyclopentyloxy)ethanoyl)pyrrolidine- 2-carboxamide | A | 2ZDL | 0.71 | |
45U | (S)-N-(4-carbamimidoylbenzyl)-1- (2-(cyclopentyloxy)ethanoyl)pyrrolidine- 2-carboxamide | H,I | 2ZFQ | 0.71 | |
2IN | N-(BENZYLSULFONYL)SERYL-N~1~-{4- [AMINO(IMINO)METHYL]BENZYL}GLYCINAMIDE | U | 1SC8 | 0.7 | |
46U | (S)-N-(4-carbamimidoylbenzyl)-1- (2-(cyclohexyloxy)ethanoyl)pyrrolidine- 2-carboxamide | H,I | 2ZFR | 0.72 | |
46U | (S)-N-(4-carbamimidoylbenzyl)-1- (2-(cyclohexyloxy)ethanoyl)pyrrolidine- 2-carboxamide | A | 2ZDM | 0.72 | |
186 | [1-(1-METHYL-4,5-DIOXO-PENT-2-ENYLCARBAMOYL)- 2-PHENYL-ETHYL]-CARBAMIC ACID BENZYL ESTER | X | 1U9Q | 0.71 |